secwatch.observer — SEC 8-K summary
======================================

Issuer:     Grace Therapeutics, Inc. (GRCE)
CIK:        0001444192
Form:       8-K
Filed at:   2025-02-13T23:59:59+00:00
Accession:  0001140361-25-004157
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Grace Therapeutics Q3 net loss $4.2M; Phase 3 STRIVE-ON meets endpoint; $15M placement
--------------------------------------------------------------------------------

- Net loss $4.2M ($0.36/sh) vs $2.4M ($0.21/sh) YoY; R&D $2.2M up from $1.4M on GTx-104 trial.
- Phase 3 STRIVE-ON safety trial met primary endpoint; NDA for GTx-104 anticipated H1 2025.
- Secured $15M upfront private placement (Nantahala Capital, ADAR1, Stonepine); up to $15M additional from warrant exercises.
- Cash at Dec 31, 2024: $11.1M, down from $23.0M at Mar 31, 2024.
- FDA provided guidance on single pivotal trial design for GTx-102 (Ataxia-Telangiectasia) toward NDA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1444192/000114036125004157/0001140361-25-004157-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1444192/000114036125004157/ef20043203_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-004157

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer